Chad Beisel
Pharmacist
12902 Usf Magnolia Dr, Tampa
Florida, 33612-9416
484-934-2646 Chad Beisel is a pharmacist in Tampa, Florida. Patients can reach him at 12902 Usf Magnolia Dr, Tampa or contact him on 484-934-2646. Active license number of Chad Beisel is PS69727 for Pharmacist in Florida.
Chad Beisel is
Complete Profile:
Chad Beisel speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
| Name: | Chad Beisel |
| Specialization: | Pharmacist |
| Credentials: | PHARMD |
| Gender: | Male |
| Location: | 12902 Usf Magnolia Dr, Tampa,
Florida, 33612-9416 |
| Phone: | 484-934-2646 |
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Chad Beisel are as mentioned below.
| NPI Number: | 1821950395 |
| NPI Enumeration Date: | 02 Dec, 2025 |
| NPI Last Update On: | 02 Dec, 2025 |
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Chad Beisel are as mentioned below.
| Specialization | License Number | State | Status | |
| Pharmacist | PS69727 | Florida | Primary | |
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
| Address: | 12902 Usf Magnolia Dr,
Tampa, Florida |
| Zip: | 33612-9416 |
| Phone Number: | -- |
Patients can reach Chad Beisel at
12902 Usf Magnolia Dr, Tampa, Florida or can
call on phone at 484-934-2646.
Comments/ Reviews:
Read all the reviews posted for Chad Beisel below. You may also share your own experience with Chad Beisel. Your feedback can help others make better decisions.
**Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 08 December, 2025.